Trevi Therapeutics (TRVI) News Today $6.26 +0.10 (+1.62%) Closing price 04:00 PM EasternExtended Trading$6.13 -0.13 (-2.08%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Northern Trust Corp raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 482,815 shares of the company's stock after buyingMay 27 at 3:03 AM | marketbeat.comWoodline Partners LP Buys 2,606,370 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)Woodline Partners LP grew its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 429.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,212,597 shares of the company's stock after acquiring an additioMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Frazier Life Sciences Management L.P. raised its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 44.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,664,774 shares of the company's stock after buying an additional 3,28May 23, 2025 | marketbeat.comTrevi Therapeutics' (TRVI) Buy Rating Reiterated at Needham & Company LLCMay 23, 2025 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of Trevi Therapeutics in a report on Tuesday.May 22, 2025 | marketbeat.comVR Adviser LLC Reduces Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)VR Adviser LLC lessened its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 63.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,266,457 shares of the company'sMay 22, 2025 | marketbeat.comTrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic CoughMay 20, 2025 | prnewswire.comPoint72 Asset Management L.P. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Point72 Asset Management L.P. bought a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,150,237 shares of theMay 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $368,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Cubist Systematic Strategies LLC purchased a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 89,309 shares of the company's stock, valued at apprMay 19, 2025 | marketbeat.comDimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Dimensional Fund Advisors LP boosted its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 86.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,353 shares of the company's stock after purchasing an additionalMay 19, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Holdings Increased by MPM Bioimpact LLCMPM Bioimpact LLC lifted its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 101.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,094,896 shares of the company's stock after purcMay 16, 2025 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comBarclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Barclays PLC grew its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 64.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,267 shares of the company's stock after buying an adMay 10, 2025 | marketbeat.comTrevi Therapeutics, Inc.: Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finanznachrichten.deTrevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation toMay 9, 2025 | marketbeat.comMarshall Wace LLP Sells 38,203 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)Marshall Wace LLP lowered its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 47.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,921 shares of the company's stock after selling 38,203 shares duriMay 8, 2025 | marketbeat.comAlly Bridge Group NY LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Ally Bridge Group NY LLC cut its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 40.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 781,489 shares of the company's stock after selling 541,311 shares duMay 4, 2025 | marketbeat.comAcuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Acuta Capital Partners LLC increased its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 165.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 771,958 shares ofMay 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Invests $8.24 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Acorn Capital Advisors LLC acquired a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 2,001,048 shares of the company's stock, valued at approximately $8,244,000. Trevi Therapeutics makes uMay 4, 2025 | marketbeat.comBoothbay Fund Management LLC Takes $387,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Boothbay Fund Management LLC acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 93,859 shares of the company's stock, valuMay 4, 2025 | marketbeat.comTrevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025May 1, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Here's WhyTrevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Time to Buy?May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Adage Capital Partners GP L.L.C. purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 2,500,000 shares of the company's stock, valued at approApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)JPMorgan Chase & Co. increased its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 120.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 221,664 shares of the company's stock after acquiringApril 30, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)XTX Topco Ltd acquired a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 67,201 shares of the company's stock, valued at approximately $277,000. XTX TopApril 28, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Silverarc Capital Management LLCSilverarc Capital Management LLC raised its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 52.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 734,234 shares of the company's stock after buying an additional 251,659 sApril 24, 2025 | marketbeat.comVivo Capital LLC Boosts Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Vivo Capital LLC increased its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 116.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,487,903 shares of the company's stock after buying an additioApril 23, 2025 | marketbeat.comTrevi Therapeutics management to meet virtually with B. RileyApril 22, 2025 | markets.businessinsider.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by AnalystsShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and three have givenApril 14, 2025 | marketbeat.comTrevi Therapeutics management to meet with Cantor FitzgeraldApril 11, 2025 | markets.businessinsider.comTraders Purchase Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) saw some unusual options trading on Wednesday. Traders acquired 2,815 call options on the stock. This represents an increase of 240% compared to the typical daily volume of 828 call options.April 11, 2025 | marketbeat.comLandscape Capital Management L.L.C. Has $215,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Landscape Capital Management L.L.C. trimmed its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 87.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,085 shares of the comApril 11, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of Trevi Therapeutics in a report on Tuesday.April 10, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Price Down 9.3% - Should You Sell?Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 9.3% - Here's WhyApril 10, 2025 | marketbeat.comTrevi Therapeutics to Participate in Upcoming April Investor ConferencesApril 3, 2025 | prnewswire.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Here's What HappenedTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Down - Time to Sell?April 2, 2025 | marketbeat.comShort Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Rises By 23.5%Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,680,000 shares, an increase of 23.5% from the February 28th total of 3,790,000 shares. Approximately 8.1% of the shares of the company are sold short. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 2.5 days.April 2, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $34,630.54 in StockTrevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. The trade was a 2.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 26, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Up 5.7% - Should You Buy?Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% Higher - Still a Buy?March 26, 2025 | marketbeat.comRosalind Advisors Inc. Has $4.38 Million Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Rosalind Advisors Inc. raised its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 41.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,062,500 shares of the company's stock after purchMarch 23, 2025 | marketbeat.comHC Wainwright Issues Negative Forecast for TRVI EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst O. Livnat now anticipates that the company will pMarch 22, 2025 | marketbeat.comQ2 EPS Estimates for Trevi Therapeutics Reduced by B. RileyTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Investment analysts at B. Riley lowered their Q2 2025 earnings estimates for Trevi Therapeutics in a research note issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of (March 22, 2025 | marketbeat.comLeerink Partnrs Issues Positive Outlook for TRVI EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for Trevi Therapeutics in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings perMarch 22, 2025 | marketbeat.comB. Riley Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)B. Riley reaffirmed a "buy" rating and issued a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday.March 20, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Earnings BeatTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected EarningsMarch 20, 2025 | marketbeat.comEarnings call transcript: Trevi Therapeutics Q4 2024 reports mixed resultsMarch 20, 2025 | uk.investing.comTREVI THERAPEUTICS Earnings Results: $TRVI Reports Quarterly EarningsMarch 20, 2025 | nasdaq.comHC Wainwright Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)HC Wainwright restated a "buy" rating and set a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday.March 20, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Price Target Cut to $24.00 by Analysts at Needham & Company LLCNeedham & Company LLC decreased their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a report on Wednesday.March 20, 2025 | marketbeat.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼1.111.03▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼84▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News IMVT News HCM News AAPG News XENE News OGN News AMRX News IBRX News APLS News MIRM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe trade war twist nobody saw comingThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRVI Stock Free TRVI Stock Alerts